Docetaxel with prednisone or prednisolone for the treatment of ...

assessments of patients and physicians. Eur Urol
1997;32 Suppl 3:86–8.
74. Chapman GB, Elstein AS, Kuzel TM, Sharifi R,
Nadler RB, Andrews A, et al. Prostate cancer
patients’ utilities for health states: how it looks
depends on where you stand. Med Decis Making
1998;18:278–86.
75. Chapman GB, Elstein AS, Kuzel TM, Nadler RB,
Sharifi R, Bennett CL. A multi-attribute model of
prostate cancer patients’ preferences for health
states. Qual Life Res 1999;8:171–80.
76. Krahn M, Ritvo P, Irvine J, Tomlinson G,
Bremner KE, Bezjak A, et al. Patient and
community preferences for outcomes in prostate
cancer: implications for clinical policy. Med Care
2003;41:153–64.
77. Sandblom G, Carlsson P, Sennfalt K, Varenhorst E.
A population-based study of pain and quality of
life during the year before death in men with
prostate cancer. Br J Cancer 2004;90:1163–8.
78. Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC,
Krahn MD. Preferences of husbands and wives for
outcomes of prostate cancer screening and
treatment. J Gen Intern Med 2004;19:339–48.
79. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM.
Utilities for prostate cancer health states in men
aged 60 and older. Med Care 2005;43:347–55.
80. Joint Formulary Committee. British National
Formulary. 49th ed. London: British Medical
Association and Royal Pharmaceutical Society of
Great Britain; 2005.
81. Chartered Institute of Public Finance and
Accountancy. Health service financial database [CD-
ROM]. London: Chartered Institute of Public
Finance and Accountancy; 2004.
82. Johannesson M, Weinstein MC. On the decision
rules of cost-effectiveness analysis. J Health Econ
1993;12:459–67.
83. Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–87.
84. Esper P, Mo F, Chodak G, Sinner M, Cella D,
Pienta KJ. Measuring quality of life in men with
prostate cancer using the functional assessment of
cancer therapy – prostate instrument. Urology
1997;50:920–8.
85. Lu G, Ades AE. Combination of direct and indirect
evidence in mixed treatment comparisons. Stat
Med 2004;23:3105–24.
86. Spiegelhalter DAT, Best N, Lunn D. WinBUGS user
manual: version 1.4. Cambridge: Medical Research
Council Biostatistics Unit; 2001.
87. Claxton K, Sculpher M, Drumond M. A rational
framework for decision making by the National
Institute for Clinical Excellence (NICE)
[discussion]. Lancet 2002;360:711–15.
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Health Technology Assessment 2007; Vol. 11: No. 2
88. Claxton K. The irrelevance of inference: a
decision-making approach to the stochastic
evaluation of health care technologies. J Health
Econ 1999;18:341–64.
89. Claxton K, Posnett J. An economic approach to
clinical trial design and research priority-setting.
Health Econ 1996;5:513–24.
90. Fenwick E, Claxton K, Sculpher M. The value of
implementation and the value of information: combined
and uneven development [CHE research paper no. 5].
York: University of York, Centre for Health
Economics; 2005.
91. Ahmad K. New progress in treatment of hormonerefractory
prostate cancer. Lancet Oncol 2004;5:706.
92. Anonymous. Systemic therapy in advanced or
metastatic prostate cancer: evaluation of drug efficacy.
[STAMPEDE] [Ongoing trial – ISRCTN78818544].
2002. URL: http://www.controlledtrials.com/isrctn/trial/|/0/78818544.html.
Accessed
16 May 2005.
93. Phase III studies with docetaxel: significant
advantage for survival in androgen-independent
prostate cancer. Dtsch Apoth Ztg 2004;144:38–40 (in
German).
94. Anonymous. Mitoxantrone: new indication. More
risky than beneficial in advanced prostate cancer.
Prescrire Int 2001;10:110–12.
95. Anonymous. Health-related QOL measurements:
key to optimal management of prostate cancer.
Drugs Ther Perspect 2000;16:13–16.
96. Arcenas AG, Karkera D, Anderson A, Krasnow SH.
Preliminary results of a phase II trial of docetaxel
(D) and mitoxantrone (M)/prednisone (P) in
patients (pts) with hormone-refractory prostate
cancer (HRPC) [conference abstract]. Proc Am Soc
Clin Oncol 2003;22:427 (abstract 1714). URL:
http://www.asco.org/portal/site/ASCO/menuitem.
34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=
76f8201eb61a7010VgnVCM100000ed730ad1RCRD
&vmview=abst_detail_view&confID=23&index=
y&abstractID=101545. Accessed 4 April 2005.
97. Arlen PM, Figg WD, Gulley J, Cox MC,
Linehan WM, Dahut W. National Cancer Institute
intramural approach to advanced prostate cancer.
Clin Prostate Cancer 2002;1:153–62.
98. Autorino R, di Lorenzo G, Damiano R,
de Placido S, d’Armiento M. Role of
chemotherapy in hormone-refractory prostate
cancer. Old issues, recent advances and new
perspectives. Urol Int 2003;70:1–14.
99. Aventis Pharma. Taxotere [web page on the
Internet]. Bridgewater, NJ: Aventis Pharma; 2004.
URL: http://www.taxotere.com/professional/
home.do. Accessed 6 January 2005.
87